Tomáš Etrych

8.4k total citations
217 papers, 6.7k citations indexed

About

Tomáš Etrych is a scholar working on Biomaterials, Biomedical Engineering and Molecular Biology. According to data from OpenAlex, Tomáš Etrych has authored 217 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 141 papers in Biomaterials, 78 papers in Biomedical Engineering and 71 papers in Molecular Biology. Recurrent topics in Tomáš Etrych's work include Nanoparticle-Based Drug Delivery (139 papers), Nanoplatforms for cancer theranostics (64 papers) and RNA Interference and Gene Delivery (36 papers). Tomáš Etrych is often cited by papers focused on Nanoparticle-Based Drug Delivery (139 papers), Nanoplatforms for cancer theranostics (64 papers) and RNA Interference and Gene Delivery (36 papers). Tomáš Etrych collaborates with scholars based in Czechia, Germany and Japan. Tomáš Etrych's co-authors include Karel Ulbrich, Petr Chytil, Blanka Řı́hová, M. Jelı́nková, J. Strohalm, Vladimír Šubr, Milada Šírová, Michal Pechar, Tomáš Mrkvan and Libor Kostka and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and ACS Nano.

In The Last Decade

Tomáš Etrych

208 papers receiving 6.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tomáš Etrych Czechia 46 4.0k 2.7k 2.4k 1.5k 1.1k 217 6.7k
Marı́a J. Vicent Spain 43 2.9k 0.7× 1.9k 0.7× 2.7k 1.1× 1.5k 1.0× 756 0.7× 150 6.5k
Vladimír Šubr Czechia 46 3.3k 0.8× 2.6k 1.0× 2.7k 1.1× 1.2k 0.8× 706 0.6× 129 7.4k
Gianfranco Pasut Italy 36 2.7k 0.7× 1.4k 0.5× 3.2k 1.3× 1.3k 0.9× 730 0.7× 109 7.1k
Pavla Kopečková United States 52 3.3k 0.8× 1.8k 0.7× 2.9k 1.2× 1.5k 1.0× 824 0.7× 136 7.2k
Paolo Caliceti Italy 41 2.2k 0.6× 1.5k 0.6× 2.4k 1.0× 1.1k 0.7× 624 0.6× 168 6.6k
Nazila Kamaly United Kingdom 31 5.0k 1.2× 4.0k 1.5× 3.6k 1.5× 878 0.6× 595 0.5× 62 9.8k
Blanka Řı́hová Czechia 43 2.8k 0.7× 1.6k 0.6× 1.7k 0.7× 978 0.7× 805 0.7× 140 5.0k
Yuanpei Li United States 38 2.8k 0.7× 2.9k 1.1× 2.1k 0.9× 688 0.5× 556 0.5× 121 6.0k
Zhuxian Zhou China 48 4.3k 1.1× 4.8k 1.8× 3.9k 1.6× 718 0.5× 904 0.8× 174 9.6k
Shigeto Fukushima Japan 39 3.9k 1.0× 2.2k 0.8× 3.7k 1.5× 1.7k 1.2× 970 0.9× 60 7.5k

Countries citing papers authored by Tomáš Etrych

Since Specialization
Citations

This map shows the geographic impact of Tomáš Etrych's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomáš Etrych with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomáš Etrych more than expected).

Fields of papers citing papers by Tomáš Etrych

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomáš Etrych. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomáš Etrych. The network helps show where Tomáš Etrych may publish in the future.

Co-authorship network of co-authors of Tomáš Etrych

This figure shows the co-authorship network connecting the top 25 collaborators of Tomáš Etrych. A scholar is included among the top collaborators of Tomáš Etrych based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomáš Etrych. Tomáš Etrych is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Klepac, Damir, Srećko Valić, Sami Kereı̈che, et al.. (2025). HPMA-based nitroxide radical containing nanoparticles with controlled radical release: Detailed physico-chemical characterization. European Polymer Journal. 225. 113727–113727.
2.
3.
Pola, Robert, Michal Pechar, Libor Kostka, et al.. (2025). Nanomedicines for Delivery of Cytarabine: Effect of Carrier Structure and Spacer on the Anti-Lymphoma Efficacy. Polymers. 17(21). 2837–2837.
4.
Sanctis, Juan Bautista De, Lukáš Kubala, Petr Chytil, et al.. (2024). Polymer nanotherapeutics with the controlled release of acetylsalicylic acid and its derivatives inhibiting cyclooxygenase isoforms and reducing the production of pro-inflammatory mediators. International Journal of Pharmaceutics. 665. 124742–124742. 2 indexed citations
5.
Henríquez, Luis Castillo, Khair Alhareth, Libor Kostka, et al.. (2024). Step‐By‐Step Standardization of the Bottom‐Up Semi‐Automated Nanocrystallization of Pharmaceuticals: A Quality By Design and Design of Experiments Joint Approach. Small. 20(25). e2306054–e2306054. 6 indexed citations
6.
Nakamura, Hideaki, et al.. (2024). Chemical modification of bradykinin-polymer conjugates for optimum delivery of nanomedicines to tumors. Nanomedicine Nanotechnology Biology and Medicine. 57. 102744–102744. 2 indexed citations
7.
Tuřánek, Jaroslav, Petr Kosztyu, Pavlína Turánek Knötigová, et al.. (2024). Long circulating liposomal platform utilizing hydrophilic polymer-based surface modification: preparation, characterisation, and biological evaluation. International Journal of Pharmaceutics. 661. 124465–124465. 3 indexed citations
8.
Chen, Junlin, Eva Miriam Buhl, Robert Pola, et al.. (2024). RGD-coated polymeric microbubbles promote ultrasound-mediated drug delivery in an inflamed endothelium-pericyte co-culture model of the blood-brain barrier. Drug Delivery and Translational Research. 14(10). 2629–2641. 3 indexed citations
9.
Šubr, Vladimír, et al.. (2024). Highly Effective Synthetic Polymer-Based Blockers of Non-Specific Interactions in Immunochemical Analyses. Polymers. 16(6). 758–758. 3 indexed citations
10.
11.
12.
Pola, Robert, Michal Pechar, Jan Pankrác, et al.. (2023). Stimuli‐Responsive Polymer Nanoprobes Intended for Fluorescence‐Guided Surgery of Malignant Head‐and‐Neck Tumors and Metastases. Advanced Healthcare Materials. 12(28). e2301183–e2301183. 3 indexed citations
13.
Hackbarth, Steffen, et al.. (2023). Singlet Oxygen In Vivo: It Is All about Intensity—Part 2. Journal of Personalized Medicine. 13(5). 781–781.
14.
Kovář, Marek, Vladimír Šubr, Martin Studenovský, et al.. (2023). Chemosensitization of tumors via simultaneous delivery of STAT3 inhibitor and doxorubicin through HPMA copolymer-based nanotherapeutics with pH-sensitive activation. Nanomedicine Nanotechnology Biology and Medicine. 56. 102730–102730.
15.
Filipová, Marcela, et al.. (2022). The Transmission and Toxicity of Polymer-Bound Doxorubicin-Containing Exosomes Derived from Human Adenocarcinoma Celxdls. Nanomedicine. 17(19). 1307–1322. 2 indexed citations
16.
Šácha, Pavel, Libor Kostka, Jiří Schimer, et al.. (2019). Inhibitor–Polymer Conjugates as a Versatile Tool for Detection and Visualization of Cancer-Associated Carbonic Anhydrase Isoforms. ACS Omega. 4(4). 6746–6756. 13 indexed citations
17.
Islam, Waliul, Jun Fang, Takahisa Imamura, et al.. (2018). Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide–Generating Agents Improves the Therapeutic Effects of Nanomedicines. Molecular Cancer Therapeutics. 17(12). 2643–2653. 83 indexed citations
18.
Neburková, Jitka, František Sedlák, Libor Kostka, et al.. (2018). Inhibitor–GCPII Interaction: Selective and Robust System for Targeting Cancer Cells with Structurally Diverse Nanoparticles. Molecular Pharmaceutics. 15(8). 2932–2945. 22 indexed citations
19.
Beztsinna, Nataliia, Bo Lou, Tomáš Etrych, et al.. (2017). Overcoming multidrug resistance using folate receptor-targeted and pH-responsive polymeric nanogels containing covalently entrapped doxorubicin. Nanoscale. 9(29). 10404–10419. 57 indexed citations
20.
Lucas, Henrike, et al.. (2016). Improved Tumor-Specific Drug Accumulation by Polymer Therapeutics with pH-Sensitive Drug Release Overcomes Chemotherapy Resistance. Molecular Cancer Therapeutics. 15(5). 998–1007. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marı́a J. Vicent Breakdown of academic impact, for papers by Vladimír Šubr Breakdown of academic impact, for papers by Gianfranco Pasut Breakdown of academic impact, for papers by Pavla Kopečková Breakdown of academic impact, for papers by Paolo Caliceti Breakdown of academic impact, for papers by Nazila Kamaly Breakdown of academic impact, for papers by Blanka Řı́hová Breakdown of academic impact, for papers by Yuanpei Li Breakdown of academic impact, for papers by Zhuxian Zhou Breakdown of academic impact, for papers by Shigeto Fukushima
Rankless by CCL
2026